Twist Bioscience
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthes...
Latest News
13 hours ago · seekingalpha.com
Twist Bioscience: Long-Term 'Buy' On AI Discovery For BiotechI believe TWST can, over time, capture more of a customer's R&D budget if initial DNA orders lead to more repeat testing and lab data work. TWST's AI drug discovery is at the heart of my growth bull case. But their diagnostics services also dovetail nicely because they could create additional demand. As customers scale personalized cancer testing, TWST could see more demand for its custom panels.
4 days ago · marketbeat.com
Twist Bioscience Q4 Earnings Call HighlightsTwist Bioscience NASDAQ: TWST reported 28% revenue growth and positive adjusted EBITDA for its fiscal fourth quarter, as demand for DNA, proteins and data used in AI drug discovery helped drive a 22% increase in full-year sales.
4 days ago · fool.com
Twist Bioscience: 3 Key Takeaways for Long-Term InvestorsFourth-quarter revenue grew 28% year over year to $126.6 million. AI drug discovery revenue reached $59.1 million in fiscal 2026.
4 days ago · seekingalpha.com
Twist Bioscience Corporation (TWST) Q4 2026 Earnings Call TranscriptTwist Bioscience Corporation (TWST) Q4 2026 Earnings Call Transcript
4 days ago · zacks.com
Twist Bioscience (TWST) Reports Q4 Loss, Beats Revenue EstimatesTwist Bioscience (TWST) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to a loss of $0.45 per share a year ago.
4 days ago · businesswire.com
Twist Bioscience Announces Fiscal 2026 Fourth Quarter and Full Year Financial ResultsSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value healthcare company, today announced financial results and business highlights for the fourth quarter and full year fiscal 2026 ended September 30, 2026. Visit the Events and Presentations page of the Investor Relations section under the “Company” tab at www.twistbioscience.com to view the detailed fiscal fourth quarter and full year 2026 earnings report and the investor presenta.
5 days ago · businesswire.com
Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a mid-cap growth and value healthcare company, today announced that a total of 17,681 restricted stock units (“RSUs”) will be granted to 19 recently hired individuals, in each case as an inducement material to their acceptance of employment with Twist. The employment inducement awards will be granted under Twist's Amended and.
8 days ago · businesswire.com
Twist Bioscience to Present at Upcoming Investor ConferencesSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value healthcare company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Adam Laponis, CFO of Twist Bioscience, will participate in fireside chats at the following upcoming investor conferences. Jefferies Global Healthcare Conference in London, UK on Tuesday, November 17; fireside chat at 3:00 pm Greenwich Mean Time 9th Annual Evercore Healt.
2 months ago · benzinga.com
Twist Bioscience Stock Hits New High, Then Retreats: What's Happening?Twist Bioscience Corp. (NASDAQ:TWST) shares are trading lower Friday, pulling back after touching a fresh 52-week high near $192 earlier in the session. Here's what you should know.
2 months ago · fool.com
Why Twist Bioscience Stock Skyrocketed This WeekThe biotech will both contribute to and draw from its findings. It'll also earn revenue from its participation.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove TWST